Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients (Q45144869)

10 December 2017

title

Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients (English)

1 reference

10 December 2017

Rodrigues P

1 reference

10 December 2017

Hering F

series ordinal

1 reference

10 December 2017

Campagnari JC

series ordinal

1 reference

10 December 2017

publication date

1 January 2004

1 reference

Prostate Cancer and Prostatic Diseases

10 December 2017

published in

1 reference

10 December 2017

1 reference

10 December 2017

1 reference

10 December 2017

page(s)

350-354

1 reference

Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

The biology of hormone refractory prostate cancer. Why does it develop?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Complications of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Malignant bone resorption: cellular and biochemical mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Pathophysiologic interactions in skeletal metastasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Inhibition of antigen-presenting cell function by alendronate in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Bisphosphonates and tumor burden

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500752

7 January 2021

Dimensions Publication ID

Identifiers

DOI

10.1038/SJ.PCAN.4500752

0 references

1009797479

0 references

1 reference